19 Apr, 2022, 09:00 ET
New Patents Protect innovative Axon™ Therapy, a Non-Invasive and Non-Pharmacological Solution for Treating Neuropathic Pain, as NeuraLace's Clinical Strategy Advances Focusing on Neuropathic Pain Related to Surgery, Trauma and Diabetic Neuropathy
SAN DIEGO , April 19, 2022 /PRNewswire/ -- NeuraLace Medical, Inc., a commercial-stage medical technology company focusing on innovative solutions for neuropathic pain care, announces the expansion of its global patent portfolio with the issuance of two new patents: US Patent No. 11,305,130 for "Devices, Systems, and Methods For Non-Invasive Chronic Pain Therapy" (issued April 19, 2022) and US Patent No. 11,273,317 for "Portable Transcutaneous Magnetic Stimulator and Systems and Methods of Use Thereof" (issued March 15, 2022).
The new patents include system and method claims for treating peripheral nerve pain using low-frequency transcutaneous magnetic stimulation, including advanced applications in wearable pain therapy technology. The patents, which last until 2039 and 2033, respectively, are part of a global patent portfolio protecting the core Axon™ Therapy and advanced applications such as robotics for applying Axon Therapy, including U.S. Patent No. 10,369,373 issued on August 6, 2019 and U.S. Patent No. 11,058,887 issued on July 13, 2021.
"We are pleased to strengthen our intellectual property protection with the addition of these new US patents," stated Keith Warner, Chief Executive Officer of NeuraLace Medical. "Along with our robust international IP portfolio, these patents bolster and expand the protection of our core Axon technology, highlighted by the use of transcutaneous magnetic stimulation as opposed to invasive and/or pharmacological solutions. The company's clinical results thus far have been impressive, and we look forward to this momentum carrying forward to the completion and publication of our formal clinical studies."
The company is in the process of expanding sites of its ongoing randomized clinical trial focusing on application of Axon therapy to neuropathic pain broadly, while also initiating a large study focusing on peripheral diabetic neuropathy, recognizing that for millions of patients the drugs used in first line therapy become ineffective or are not well tolerated, and other modalities of treatment are needed.
About NeuraLace Medical
Privately held NeuraLace Medical, Inc., headquartered in San Diego, Calif., is committed to leading the charge in non-invasive chronic pain management and sustainable relief. Our mission to end chronic pain inspired us to develop Axon Therapy, with the goal of being the first non-invasive, non-addictive way to effectively treat chronic nerve pain.
With its unique product portfolio, protected by property patents and patent applications, NeuraLace Medical is well positioned to establish a leadership position in the medical device market. For more information, please visit www.neuralacemedical.com.
For more information, please contact:
Chief Executive Office
SOURCE Neuralace Medical, Inc.
Share this article